BioFIT Event’s Post

Your weekly life science industry specific updates are here! A lot can happen in a week, but here a few notable insights across our specialist areas: - Corden Pharma - A Full-Service CDMO 🤝 are making a significant move with a €900 million investment over the next 3 years to expand its peptide platform in the USA and Europe. 💊 - MSD Animal Health acquires Elanco Aqua for $1.3 billion in cash, with approximately $1.05-$1.1 billion in net proceeds available for debt pay down in the third quarter of 2024. 🐶 - Illumina acquires Fluent BioSciences Inc. to accelerate single-cell analysis and discovery to a broader customer base. 👩🔬 - Huma raises $80M Series D Funding to launch Huma Cloud Platform. It is great to see that there is a lot of movement in the space and we are excited to see how these announcements develop! If you have some news to shout about please let us know in the comments.... ⬇ #science #update #industrynews #genomics #CDMO #animalhealth #aquisition

The FDA Modernization Act 2.0 opened up the gates for advanced toxicity and efficacy screening technology to be used as an alternative for animal testing in preclinical studies. Animal testing, while ethically questionable, is also extremely expensive and time consuming-- not good news for the investor. With this recent legislative change in mind, Imagine Biotech offers scientific due diligence services, including advanced toxicity and efficacy screening, to investors in order to de-risk biotech investment portfolios.

**PRESS RELEASE** Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time. Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13 million CND, means for Kane as an important step in becoming a market leader in the growing high-value wound care and dermatological markets. The transaction, which focuses the company and significantly improves the balance sheet, will provide the necessary capital to achieve key milestones such as commercial launches and global growth, as well as our clinical programs in both wound care and acne. Participants can register for the webinar by using this link: https://lnkd.in/gnPdvbra #Biotech #BioTechnology #Biofilm #Biofilms #PressRelease #BusinessGrowth #WoundCare #HumanHealth #Innovation #SmallCap #Research #Development #KaneBio

INOVOTION will be at the European Partnership for Alternative Approaches to Animal Testing (EPAA) Annual Conference 2024, November 13, 2024, in Brussels! This crucial event organised by the European Commission focuses on accelerating the adoption of New Approach Methodologies (NAMs) within current EU regulatory frameworks. Key themes include: - Regulatory acceptance of NAMs - Challenges in implementing NAMs across different sectors - Strategies for enhancing NAM uptake in safety assessments - Harmonizing NAM approaches across EU member states Our CEO, Jean Viallet, will be attending to engage in discussions on these vital topics. INOVOTION's 3Rs-compliant CAM model aligns perfectly with the conference's goals, offering an innovative approach to reduce animal testing while maintaining robust preclinical results. Jean Viallet looks forward to exploring how our technology can contribute to the broader adoption of NAMs in various research fields, including oncology, and how it fits within existing and evolving EU regulations. Connect with Jean Viallet at the conference to discover how INOVOTION's methods can support your research while adhering to ethical standards and regulatory requirements. Learn more about our 3Rs-compliant services: https://lnkd.in/gWQJncb Join us in advancing ethical and efficient preclinical testing at EPAA 2024! #preclinical  #drugdiscovery  #NAMs 

🚀 InSphero’s Mission to Reduce Animal Testing in Drug Discovery - an Interview with LSCV 🧬   We had the opportunity to sit down with the Swiss League Against Animal Testing (LSCV - Ligue suisse contre l'expérimentation animale et pour les droits des animaux) to discuss the critical need for advancements in biotechnology and the limitations of traditional animal testing in drug development. 🧪   At #InSphero, we are dedicated to developing highly predictive and scalable 3D in vitro models that can #reduce - and eventually, #replace - the need for animal testing in early-stage pharmaceutical research.   This interview underscores the ethical concerns around #animaltesting and its inability to represent the full spectrum of human diversity. By shifting to patient-derived models, we aim to lower the high attrition rates seen in clinical trials and provide more precise, human-relevant data from the start. Together, we are pushing for a future where drug discovery is both ethical and efficient. 🙌 Watch the full video in the comments below 👇 Thank you, Athénaïs Python, for the great interview! Madhu Lal Nag, MBS PhD Jan Lichtenberg Olivier Frey Paul Edgard Clémençon Filip Henzler Wolfgang Moritz Burcak Yesildag Bruno Filippi Francisco Verdeguer Laure-Anne Ligeon Stina Näslund Marion Bavand Dr. Henriette Schneider David Fluri Arumugham (Ragoo) Raghunathan Arnab China, PhD Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova   #AnimalTestingAlternatives #Biotechnology #DrugDiscovery #InVitroModels #PharmaInnovation #InSphero #LSCV #EthicalScience

INOVOTION will be at the European Partnership for Alternative Approaches to Animal Testing (EPAA) Annual Conference 2024, November 13, 2024, in Brussels! This crucial event organised by the European Commission focuses on accelerating the adoption of New Approach Methodologies (NAMs) within current EU regulatory frameworks. Key themes include: - Regulatory acceptance of NAMs - Challenges in implementing NAMs across different sectors - Strategies for enhancing NAM uptake in safety assessments - Harmonizing NAM approaches across EU member states Our CEO, Jean Viallet, will be attending to engage in discussions on these vital topics. INOVOTION's 3Rs-compliant CAM model aligns perfectly with the conference's goals, offering an innovative approach to reduce animal testing while maintaining robust preclinical results. Jean Viallet looks forward to exploring how our technology can contribute to the broader adoption of NAMs in various research fields, including oncology, and how it fits within existing and evolving EU regulations. Connect with Jean Viallet at the conference to discover how INOVOTION's methods can support your research while adhering to ethical standards and regulatory requirements. Learn more about our 3Rs-compliant services: https://lnkd.in/e8b-5zR Join us in advancing ethical and efficient preclinical testing at EPAA 2024! #preclinical  #drugdiscovery  #NAMs 

🌟 Great NEWS from #polishbiotech company : Bioceltix 🚀 The results from Bioceltix's #clinicaltrial are groundbreaking❗️ ❇️ 64% of horses 🐴 treated with BCX-EM showed clinical improvement in arthritis symptoms compared to 33% in the placebo group, indicating clear therapeutic benefits. ❇️ The results are statistically significant, supporting the product's efficacy in treating equine arthritis. ❇️ BCX-EM offers a safer and more effective alternative to traditional anti-inflammatory treatments, with the potential to revolutionize equine care by addressing the root cause of inflammation. ❇️ Its allogeneic #stemcell #technology 🧫 allows for scalable production, making it accessible to a broader market. "The results of the current study are similar to the results of the study for dogs, which is in line with our expectations and intuition, because they concern similar therapeutic areas. We therefore have a chance to register another #medicinalproduct, this time for horses. It is also worth noting that both products, although manufactured from #cells of different species, are based on the same production philosophy and technological #platform. This is very important to us, because it confirms that our approach is correct and #effective" - comments Paweł Wielgus, PhD, Member of the Management Board of Bioceltix. More details (in PL) 👉 https://lnkd.in/dNS6ZsPR

We at NordicDx are proud to announce significant development in our partnership with Assaya, where we recently have integrated a D-dimer LFA-based RDT developed by nal von Minden GmbH into our NordicDX platform, based on the AssayaDx system. This milestone represents a substantial advancement in our commitment to enhancing diagnostic capabilities within healthcare, animal health, aquaculture, agriculture, food safety, and environmental testing in the Nordic countries and beyond. This #RDT biomarker is specifically designed to detect fibrin coagulation (micro clotting) suspected of conditions like disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT), and pulmonary embolism (PE). This opens new doors for a deeper understanding of conditions such as #LongCovid and #SickleCellAnemia. Even with a weak signal detection of .24 ug/ml, below the clinical limit of detection (LOD) of .50 ug/ml, the #iaX Rapid Diagnostic Reader (RDR) demonstrates its capacity to detect and quantify weak positive signals. This underscores the precision and effectiveness of our platform. We encourage everyone working within the relevant sectors in the Nordic countries to contact us for a discussion on how our platform can contribute to digitizing and quantifying RDTs in real-time, thereby transforming diagnostic testing. NordicDx as is actively looking for partnerships with recognized brands and distributors that have achieved EU approval for their antigen, antibody, and biomarker LFA-based RDTs for integration into our platform. For more information or to discuss potential collaborations, please contact Tommy Selnes and Elisabeth Lassa. Let’s together set a new standard for diagnostics by leveraging the latest advances in technology and collaboration.  

Seattle biotech friends and colleagues, please join us August 29th, 8:00 AM - 4:00 PM for an exciting Lunch & Learn session, focusing on New Approaches to Non-Clinical Development in the 21st Century. Here's what to expect: 1. Cutting-Edge Insights: Our expert will delve into the latest advancements in preclinical research, exploring innovative methodologies and strategies, and considerations to effectively partner with CROs 2. Interactive Discussion: Join us for an engaging discussion where you can ask questions, have a 1:1 with our expert, share your insights, and connect with fellow professionals. 3. Explore CRADL: Discover Charles River's turnkey vivarium first-hand, located in Seattle and learn about how our services can assist with accelerating your drug development timelines. Don't miss out! Register NOW using the link below! #biotech #contractvivarium #vivariumrental #research #CRADL #drugdiscovery #seattlebiotech #drugdevelopment #charlesriver #lifesciences

In the realm of preclinical research, the ethical use of animals has always been a topic of significant concern. With advancements in technology and data analysis, there’s a growing potential to minimize, and possibly replace, the need for animal testing. This is where the collaboration between Charles River Laboratories and Sanofi comes into play, marking a pivotal step towards more humane and innovative research methodologies. Heres 3 MAJOR talking points: Virtual Control Groups (VCGs) Initiative: Charles River Laboratories and Sanofi are collaborating on a project to reduce animal usage in preclinical research. Instead of live animals, they will use virtual control animals developed using retrospective datasets. These VCGs will serve as a replacement for traditional control groups. Data-Driven Approach: VCGs are based on robust historical study data and complex statistical methodology. By leveraging this historical information, researchers can reduce the need for control group animals while still obtaining meaningful study results. Machine Learning and Toxicology: Under this partnership, Charles River will combine machine learning and toxicology to create VCGs. The initiative is part of Charles River’s broader effort called the Alternative Methods Advancement Project, which aims to research alternatives to animal testing12. This innovative approach has the potential to advance sustainable science by minimizing reliance on animal models in preclinical research. 🌱🔬 https://lnkd.in/eZnpZdCx #CRO #ClinicalResearch #testing #animals #animaltesting #charlesriver #sanofi #lifescience #BIO